Zydus Lifesciences Limited has informed the Exchange about press release dated 04-Aug-2022 titled Zydus receives final approval from the USFDA for Ivermectin Cream and Zydus receives final approval from the USFDA for Empagliflozin Tablets
Press Release Aug 04 2022
Filed with NSE · · 3 pages · English
Summary by 6ix AI
This filing is a press release from Zydus Lifesciences Limited reporting two final approvals from the USFDA for new products. The first approval is for Ivermectin Cream, which is used to treat rosacea and will be manufactured in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jul 26 2022
- Press Release Jul 21 2022
- Press Release Jul 18 2022
- Press Release Jul 11 2022
- Press Release Jul 08 2022
Later from Zydus Lifesciences
- Press Release Aug 05 2022
- Press Release Aug 11 2022
- Press Release Aug 30 2022
- Press Release Aug 31 2022
- Press Release Sep 07 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences